- Home
- UAL vs IQV Comparison
UAL vs IQV Comparison
Compare UAL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAL | IQV |
|---|---|---|
| Founded | 1934 | 1982 |
| Country | United States | United States |
| Employees | 87000 | 93000 |
| Industry | Air Freight/Delivery Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 35.1B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UAL | IQV |
|---|---|---|
| Price | $125.85 | $243.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | $130.12 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 3.8M | 1.4M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.94 | 4.67 |
| EPS | ★ 4.60 | 1.61 |
| Revenue | ★ $37,736,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $11.70 | $6.77 |
| Revenue Next Year | $5.06 | $5.89 |
| P/E Ratio | ★ $27.20 | $150.13 |
| Revenue Growth | 3.23 | ★ 41.60 |
| 52 Week Low | $84.64 | $154.50 |
| 52 Week High | $138.77 | $251.36 |
Technical Indicators
Market Signals| Indicator | UAL | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 66.85 |
| Support Level | $87.53 | $220.71 |
| Resistance Level | $137.07 | $247.52 |
| Average True Range (ATR) | 4.07 | 7.73 |
| MACD | 0.08 | 0.46 |
| Stochastic Oscillator | 49.02 | 80.58 |
Price Performance
Historical ComparisonAbout UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.
About IQV IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.